STL Volume 13 Number 1
Update on Drugs and Drug News – February 2008
Update on Anti-psoriatic Agent Ustekinumab CNTO 1275, Anti-arthritic Agent Tocilizumab Actemra®, Neurotoxin Botulinum Toxin Type A
Reloxin®, and news from The National Institute for Health and Clinical Excellence (NICE) in the UK.
Novel Agents for Intractable Itch
There exists a multitude of medical conditions that cause intractable itch, or pruritus. These novel antipruritic agents will be explored in this review.
Psoriasis as the Marker of Underlying Systemic Disease
Psoriasis is associated with comorbidities that include metabolic syndrome and increased cardiovascular risk. These conditions share etiologic features and health consequences that directly correlate with the severity of psoriatic disease.
